27/02/2026
🔬 Modulight Spotlights: LASER-SHARP RESEARCH – February 2026 🔬
This month, we’re excited to highlight groundbreaking work from Professor Hirofumi Hanaoka’s team at Kansai Medical University, Photo-ImmunoTherapy Research Institute.
The team has developed a novel peptide-based photoimmunotherapy drug targeting PD-L1, a protein expressed on many cancer cells. In preclinical studies, tumor growth was significantly suppressed and overall survival was extended when the drug was activated using near-infrared light with the ML7710 laser system.
💡 Why this matters:
Compared to antibody-based therapies, this peptide-based approach may offer:
• Reduced production costs
• Rapid tumor accumulation
• Improved tumor pe*******on
• Faster systemic clearance — potentially reducing photosensitivity risks
This research represents a promising step forward in precision photoimmunotherapy and translational cancer treatment.
Read more about this exciting advancement here:
👉 https://modulight.com/laser-sharp-research/2026-02/